Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer - PubMed
3 hours ago
- #immunotherapy
- #Siglec
- #pancreatic cancer
- Cancer cell-derived sialylated IgG (SIA-IgG) is overexpressed in pancreatic cancer cells.
- SIA-IgG inhibits macrophage phagocytosis and induces an M2-like immunosuppressive phenotype via Siglec-7/9/10 interactions.
- SIA-IgG and TGF-β1 form a positive feedback loop, promoting immune evasion in pancreatic ductal adenocarcinoma (PDAC).
- Blocking SIA-IgG with monoclonal antibodies reverses PDAC's immunosuppressive microenvironment, showing therapeutic potential.
- The SIA-IgG/Siglec axis is identified as a promising immunotherapeutic target for PDAC.